Innoviva (INVA) Stock Price, News & Analysis

Company Overview

Innoviva, Inc. is a biopharmaceutical company focused on developing and commercializing healthcare products through strategic partnerships, royalty arrangements and investments in biotechnology businesses. The company’s portfolio has historically centered on respiratory medicines, with rights connected to products developed with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Breo Ellipta.

Innoviva generally operates as an asset-focused healthcare company rather than as a traditional commercial pharmaceutical manufacturer. It receives royalties and other economic benefits from partnered products marketed in multiple international markets, while pursuing additional opportunities in biopharmaceutical and healthcare companies. Its portfolio has also included an investment in Armata Pharmaceuticals, which is developing bacteriophage-based therapies intended to treat drug-resistant bacterial infections.

The company was previously known as Theravance, Inc. and adopted the Innoviva name in 2016 as its business evolved toward a royalty and strategic-investment model. Innoviva is headquartered in the United States and relies substantially on partners and affiliated companies for the development, regulatory approval and commercialization of its products. Pavel Raifeld serves as the company’s chief executive officer.

Key Stats

• Today's Range: $20.35 to $20.78
• 50-Day Range: $20.24 to $21.81
• 52-Week Range: $16.52 to $25.15
• Volume: 623,372 shs
• Average Volume: 984,056 shs
• Market Capitalization: $1.50 billion
• P/E Ratio: 5.06
• Dividend Yield: N/A
• Price Target: $34.80
• Consensus Rating: Hold

Innoviva Stock Analysis - MarketRank™

Innoviva scored higher than 56% of companies evaluated by MarketBeat, and ranked 439th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Innoviva has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Innoviva has a consensus price target of $34.80, representing about 67.8% upside from its current price of $20.74.

Amount of Analyst Coverage

Innoviva has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -7.79%

Earnings Growth

Earnings for Innoviva are expected to decrease by -7.79% in the coming year, from $2.31 to $2.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Innoviva is 5.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Innoviva is 5.06, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.

Price to Earnings Growth Ratio

Innoviva has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Innoviva has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.09% of the float of Innoviva has been sold short.

Short Interest Ratio / Days to Cover

Innoviva has a short interest ratio ("days to cover") of 9.31.

Change versus previous month

Short interest in Innoviva has recently increased by 2.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innoviva does not currently pay a dividend.

Dividend Growth

Innoviva does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.82

News Sentiment

Innoviva has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Innoviva this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innoviva insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.01% of the stock of Innoviva is held by insiders.

Percentage Held by Institutions

99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INVA
• Previous Symbol: NASDAQ:THRX
• CIK: 1080014
• Web: www.inva.com
• Phone: (650) 238-9600
• Fax: 650-827-8690
• Employees: 159
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Innoviva: $34.80
• High Price Target: $46.00
• Low Price Target: $17.00
• Potential Upside/Downside: +67.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.10
• Trailing P/E Ratio: 5.06
• Forward P/E Ratio: 8.98
• P/E Growth: 2.99
• Net Income: $271.17 million
• Net Margins: 81.19%
• Pretax Margin: 95.32%
• Return on Equity: 28.03%
• Return on Assets: 20.19%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 16.01
• Quick Ratio: 15.18

Sales & Book Value

• Annual Sales: $411.33 million
• Price / Sales: 3.64
• Cash Flow: $5.03 per share
• Price / Cash Flow: 4.12
• Book Value: $15.71 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 72,250,000
• Free Float: 70,793,000
• Market Cap: $1.50 billion
• Optionable: Optionable
• Beta: 0.33